

Governors not later than August 15, 1995.

A. Federal Reserve Bank of Chicago
(James A. Bluemle, Vice President) 230
South LaSalle Street, Chicago, Illinois
60690:

1. *Ida Grove Bancshares, Inc.*, Ida
Grove, Iowa; to engage *de novo* in
making and servicing loans, pursuant to
§ 225.25(b)(1) of the Board's Regulation
Y.

Board of Governors of the Federal Reserve
System, July 25, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-18694 Filed 7-28-95; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration on Aging

White House Conference on Aging

AGENCY: White House Conference on
Aging, AoA, HHS.

ACTION: Notice of meeting.

SUMMARY: Notice is hereby given,
pursuant to Title II of the Older
Americans Act Amendments of 1987,
Pub. L. 100-175 as amended by Pub. L.
102-375 and Pub. L. 103-171, that the
1995 White House Conference on Aging
Advisory Committee on Disabilities will
hold a meeting on Thursday, August 10,
1995 from 10 a.m. to 2:30 p.m. More
specific information on the location of
the meeting can be obtained by calling
the telephone number given below.

The meeting of the Committee shall
be open to the public. Records shall be
kept of all Committee proceedings and
will be available for public inspection at
501 School Street, SW, 8th Floor,
Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT:
White House Conference on Aging, 501
School Street, SW, 8th Floor,
Washington, DC 20024; telephone (202)
245-7116.

Dated: July 25, 1995.

Fernando M. Torres-Gil,

Assistant Secretary for Aging.

[FR Doc. 95-18701 Filed 7-28-95; 8:45 am]

BILLING CODE 4130-02-M

Food and Drug Administration

[Docket No. 95F-0191]

General Electric Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing
that the General Electric Co. has filed a
petition proposing that the food additive
regulations be amended to provide for
the safe use of polyestercarbonate resins
produced by the condensation of 4,4'-
isopropylidenediphenol, carbonyl
chloride, terephthaloyl chloride, and
isophthaloyl chloride such that the
finished resins are composed of 45 to 85
percent ester of which up to 55 percent
is the terephthaloyl isomer, as articles or
components of articles in contact with
food.

DATES: Written comments on the
petitioner's environmental assessment
by August 30, 1995.

ADDRESSES: Submit written comments
to the Dockets Management Branch
(HFA-305), Food and Drug
Administration, rm. 1-23, 12420
Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:
Richard H. White, Center for Food
Safety and Applied Nutrition (HFS-
216), Food and Drug Administration,
200 C St. SW., Washington, DC 20204,
202-418-3094.

SUPPLEMENTARY INFORMATION: Under the
Federal Food, Drug, and Cosmetic Act
(sec. 409(b)(5) (21 U.S.C. 348(b)(5))),
notice is given that a food additive
petition (FAP 5B4470) has been filed by
the General Electric Co., One Lexan
Lane, Mt. Vernon, IN 47620-9364. The
petition proposes to amend the food
additive regulations in § 177.1585
Polyestercarbonate resins (21 CFR
177.1585) to provide for the safe use of
polyestercarbonate resins produced by
the condensation of 4,4'-
isopropylidenediphenol, carbonyl
chloride, terephthaloyl chloride, and
isophthaloyl chloride such that the
finished resins are composed of 45 to 85
percent ester of which up to 55 percent
is the terephthaloyl isomer, as articles or
components of articles in contact with
food.

The potential environmental impact
of this action is being reviewed. To
encourage public participation
consistent with regulations promulgated
under the National Environmental
Policy Act (40 CFR 1501.4(b)), the
agency is placing the environmental
assessment submitted with the petition
that is the subject of this notice on
public display at the Dockets
Management Branch (address above) for
public review and comment. Interested
persons may, on or before August 30,
1995, submit to the Dockets
Management Branch (address above)
written comments. Two copies of any

comments are to be submitted, except
that individuals may submit one copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the office
above between 9 a.m. and 4 p.m.,
Monday through Friday. FDA will also
place on public display any
amendments to, or comments on, the
petitioner's environmental assessment
without further announcement in the
Federal Register. If, based on its review,
the agency finds that an environmental
impact statement is not required and
this petition results in a regulation, the
notice of availability of the agency's
finding of no significant impact and the
evidence supporting that finding will be
published with the regulation in the
Federal Register in accordance with 21
CFR 25.40(c).

Dated: July 14, 1995.

George W. Pauli,

*Acting Director, Office of Premarket
Approval, Center for Food Safety and Applied
Nutrition.*

[FR Doc. 95-18626 Filed 7-28-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 95E-0093]

Determination of Regulatory Review Period for Purposes of Patent Extension; NISOCOR

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA) has determined
the regulatory review period for
NISOCOR and is publishing this notice
of that determination as required by
law. FDA has made the determination
because of the submission of an
application to the Commissioner of
Patents and Trademarks, Department of
Commerce, for the extension of a patent
which claims that human drug product.

ADDRESSES: Written comments and
petitions should be directed to the
Dockets Management Branch (HFA-
305), Food and Drug Administration,
rm. 1-23, 12420 Parklawn Dr.,
Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:
Brian J. Malkin, Office of Health Affairs
(HFY-20), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-443-1382.

SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98-417)
and the Generic Animal Drug and Patent
Term Restoration Act (Pub. L. 100-670)
generally provide that a patent may be